載入...
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
BACKGROUND: Patients with advanced melanoma are faced with a poor prognosis and, until recently, limited treatment options. Ipilimumab, a novel immunotherapy that blocks cytotoxic T-lymphocyte-associated antigen-4, was the first agent to improve survival of patients with advanced melanoma in a rando...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4029467/ https://ncbi.nlm.nih.gov/pubmed/24423086 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-32-82 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|